318 related articles for article (PubMed ID: 29848685)
41. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
42. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
43. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
44. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
45. Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
Anticancer Res; 2018 Jan; 38(1):107-112. PubMed ID: 29277762
[TBL] [Abstract][Full Text] [Related]
46. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis.
Lee KS; Kim BH; Oh HK; Kim DW; Kang SB; Kim H; Shin E
Cancer Sci; 2018 Sep; 109(9):2957-2969. PubMed ID: 29949671
[TBL] [Abstract][Full Text] [Related]
47. The Balance of CD8-Positive T Cells and PD-L1 Expression in the Myocardium Predicts Prognosis in Lymphocytic Fulminant Myocarditis.
Hiraiwa H; Morimoto R; Tsuyuki Y; Ushida K; Ito R; Kazama S; Kimura Y; Araki T; Mizutani T; Oishi H; Kuwayama T; Kondo T; Okumura T; Murohara T
Cardiology; 2024; 149(1):28-39. PubMed ID: 37827123
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer.
Koganemaru S; Inoshita N; Miura Y; Miyama Y; Fukui Y; Ozaki Y; Tomizawa K; Hanaoka Y; Toda S; Suyama K; Tanabe Y; Moriyama J; Fujii T; Matoba S; Kuroyanagi H; Takano T
Cancer Sci; 2017 May; 108(5):853-858. PubMed ID: 28267224
[TBL] [Abstract][Full Text] [Related]
50. The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
Nishi M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Ishikawa D; Wada Y; Shimada M
Anticancer Res; 2018 Jun; 38(6):3387-3392. PubMed ID: 29848687
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
Wu Z; Yang L; Shi L; Song H; Shi P; Yang T; Fan R; Jiang T; Song J
Biomed Res Int; 2019; 2019():8014627. PubMed ID: 31275983
[TBL] [Abstract][Full Text] [Related]
52. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
[No Abstract] [Full Text] [Related]
53. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
54. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
55. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.
Chintakuntlawar AV; Rumilla KM; Smith CY; Jenkins SM; Foote RL; Kasperbauer JL; Morris JC; Ryder M; Alsidawi S; Hilger C; Bible KC
J Clin Endocrinol Metab; 2017 Jun; 102(6):1943-1950. PubMed ID: 28324060
[TBL] [Abstract][Full Text] [Related]
56. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
[TBL] [Abstract][Full Text] [Related]
57. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
58. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
Zhou T; Xu D; Tang B; Ren Y; Han Y; Liang G; Wang J; Wang L
Anticancer Drugs; 2018 Oct; 29(9):904-910. PubMed ID: 30085937
[TBL] [Abstract][Full Text] [Related]
59. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract][Full Text] [Related]
60. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
Rodrigues JM; Nikkarinen A; Hollander P; Weibull CE; Räty R; Kolstad A; Amini RM; Porwit A; Jerkeman M; Ek S; Glimelius I
Br J Haematol; 2021 May; 193(3):520-531. PubMed ID: 33686666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]